A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Cancer|Metastatic Breast Cancer|Metastatic Pancreatic Cancer|Metastatic Gastric Cancer|Metastatic Lung Cancer|Metastatic Ovary Cancer|Oesophageal Cancer|Endometrial Cancer|Advanced Solid Tumor
Interventions: DRUG: IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
Sponsor: Institut Paoli-Calmettes
Collaborators: Innate Pharma